PG19 COST-UTILITY-ANALYSIS OF PEGINTERFERON ALFA-2B PLUS RIBAVIRIN VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS INITIAL THERAPY FOR CHINESE NAIVE PATIENTS WITH CHRONIC HEPATITIS C
May 1, 2006, 00:00
10.1016/S1098-3015(10)64446-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)64446-4/fulltext
Title :
PG19 COST-UTILITY-ANALYSIS OF PEGINTERFERON ALFA-2B PLUS RIBAVIRIN VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS INITIAL THERAPY FOR CHINESE NAIVE PATIENTS WITH CHRONIC HEPATITIS C
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64446-4&doi=10.1016/S1098-3015(10)64446-4
First page :
Section Title :
Open access? :
No
Section Order :
355